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ess: vincent.cottin@chuSummary Rheumatoid arthritis (RA)-associated constrictive bronchiolitis is a
severe condition with no established efficient treatment. A 55-year-old woman
with seropositive RA developed rapidly progressive constrictive bronchiolitis
confirmed by lung biopsy. Her clinical condition worsened despite steroids and
azathioprine. Treatment with etanercept—a tumor necrosis factor (TNF)-a
inhibitor—combined with methotrexate, resulted in a marked improvement of both
her clinical condition and pulmonary function tests. Treatment with TNF-a inhibitors
and methotrexate may be proposed in RA-associated constrictive bronchiolitis, a
severe condition hitherto not amenable to improvement.
& 2004 Elsevier Ltd. All rights reserved.Introduction
Constrictive bronchiolitis with airflow obstruction is
a rare but severe manifestation of rheumatoid
arthritis (RA).1,2 Treatment with steroids and/orElsevier Ltd. All rights reserv
35 70 72;
-lyon.fr (V. Cottin).immunosuppressive drugs usually does not prevent
evolution toward chronic respiratory failure.
Tumor necrosis factor (TNF)-a inhibition using a
chimeric monoclonal anti-TNF-a antibody (inflixi-
mab) or a soluble TNF-a receptor (etanercept) has
become a major treatment in patients with
refractory or steroid-dependent RA.3 Here we
report improvement of refractory RA-associated
bronchiolitis in a patient treated with etanercept
and methotrexate.ed.
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Figure 2 HRCT of the chest (left upper lobe) showing
centrilobular nodules (arrow), bronchiectases, and
branching linear opacities (arrowhead).
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A non-smoker woman born in 1947 developed
seropositive RA in 1985. She was treated with
low-dose prednisone until 1990, when oral metho-
trexate (10mg/week) was initiated, with efficient
control on clinical symptoms. She never received
penicillamine nor tiopronine. In May 2002, basilar
inspiratory crackles were found at pulmonary
auscultation. There was no dyspnea and pulmonary
function tests were normal: forced expiratory
volume in 1 s (FEV1): 2.78 L (105% of predicted);
forced vital capacity (FVC): 3.01 L (98% of pre-
dicted) (Fig. 1). Methotrexate was stopped with the
hypothesis of emerging drug-induced pneumonitis,
which was ruled out by high-resolution computed
tomography (HRCT) of the chest (which only
showed mild branching linear opacities). Bronch-
oalveolar lavage showed no bacteria. Prednisone
5mg/d was resumed.
Progressive dyspnea on exertion was noted in
September 2002, without exacerbation of the
rheumatologic symptoms. PaO2 at rest was
8.1 kPa. The chest radiograph was normal. HRCT
of the chest showed branched opacities (Fig. 2) and
mild peripheral cylindric bronchiectases but no
mosaic pattern of lung attenuation. Lung function
was markedly impaired: in October, FEV1 was 1.25 L
(48% of predicted); FVC 2.49 L (79% of predicted);
FEV1/FVC 50%; residual volume (RV) 2.46 L (130% of
predicted), and RV/total lung capacity (TLC) ratio
50%. Videothoracoscopic lung biopsy demonstrated
diffuse inflammation of the bronchioles, with aFigure 1 Evolution of post-bronchodilatator FEpattern including chronic bronchiolar fibrosis nar-
rowing the bronchiolar lumen and/or bronchiolar
destruction, cellular inflammatory bronchiolitis
with peribronchiolar inflammation and fibrosis
(Fig. 3). A diagnosis of acute and chronic RA-
associated constrictive bronchiolitis was made.
Prednisone was increased at 1mg/kg/d and
azathioprine 100mg/d was started in November
2002.
The respiratory condition of the patient contin-
ued to deteriorate with worsening dyspnea (NYHA
class III). In May 2003, FEV1 was 0.88 L (34% of
predicted), FVC 1.86 L (60%), and RV/TLC ratio 54%.
PaO2 at rest was 7.52 kPa and long-term oxygen
therapy was started (18 h/d). Azathioprine wasV1 and FVC under treatment by etanercept.
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Figure 3 Bronchiolitis: (A) inflammatory cells in the
mucosa, submucosa, and bronchiolar wall, with dense
peribronchiolar lymphoid infiltrates (HES,  25); (B)
lymphoid cells, capillaries, and fibrosis of the bronchiolar
wall at high magnification (HES,  40).
Etanercept in constrictive bronchiolitis 513discontinued, and etanercept treatment (Enbrel,
Immunex, Seattle, WA) was instituted (25mg twice a
week subcutaneously) in association with metho-
trexate 10mg/week in order to increase the efficacy
of etanercept. Prednisone was progressively tapered
to 0.75mg/kg/d. In March 2004, the respiratory
clinical condition of the patient had improved
markedly: she could cope again with her domestic
activities and was able to walk 1 km. Dyspnea was
NYHA class II, FEV1 was 1.43 L (56% of predicted)
(Fig. 1), FVC 2.93 L (98%), and RV/TLC ratio 48%.
PaO2 at rest was 9.6 kPa and oxygen therapy could
be stopped. The patient had no joint pain. Etaner-
cept treatment was continued with methotrexate
10mg/week and prednisone 0.5mg/kg/d. Both
drugs were well tolerated by the patient.Discussion
This is the first report documenting subjective and
objective improvement using a TNF-a inhibitor andmethotrexate in a patient with biopsy proven RA-
associated constrictive bronchiolitis. Our patient
presented with typical characteristics of constric-
tive bronchiolitis including female gender, age
(50–60 years), long-standing RA, branched opaci-
ties on HRCT of the chest and severe airflow
obstruction unresponsive to prednisone and immu-
nosuppressive drugs.
Etanercept is a dimeric fusion protein which
specifically binds to TNF-a, blocking its interaction
with cell-surface TNF-a receptors, thereby render-
ing TNF-a biologically inactive. The role of TNF-a in
the pathogenesis of bronchiolitis has been assessed
in animal models of post-transplant obliterative
bronchiolitis with either lung, tracheal, or bron-
chial allografts.4–6 In a mouse model of tracheal
transplantation, expression of inflammatory cyto-
kines including TNF-a was increased in the trans-
planted airways during the course of obliterative
bronchiolitis. Blockade of TNF-a with TNFR:Fc
(equivalent to etanercept) significantly decreased
tracheal obliteration and reduced ciliated epithe-
lial injury.4 In a porcine model of post-transplant
obliterative bronchiolitis, TNF-a inhibition with
infliximab reduced inflammation, epithelial loss,
fibrosis, and obliteration early in the development
of obliterative bronchiolitis.5
TNF-a inhibitors combined with methotrexate
have become a standard treatment of several
inflammatory diseases, such as RA3 or Crohn’s
disease. TNF-a has also been implicated as a
mediator in the pathogenesis of lung fibrosis or
sarcoidosis. Case reports suggest the potential
efficacy of TNF-a inhibitors in some pulmonary
disorders. Positive responses to anti-TNF-a have
been observed in Wegener’s granulomatosis7 and
sarcoidosis.8 In addition, infliximab tested in six
patients with RA-associated interstitial lung disease
induced stabilisation of the pulmonary disease in
most cases.9,10
In conclusion, we report a beneficial effect of
TNF-a blockade in a patient with biopsy proven RA-
associated bronchiolitis, a condition hitherto not
amenable to improvement.References
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